Crystallization (Comment) | Organism |
---|---|
molecular docking of inhibitors | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
4-[5-(4,6-dimethoxy-1,3,5-triazin-2-yl)-1,2-oxazol-3-yl]-N,N-dimethylaniline | in a model structure, the dimethylamine is in front of the zinc atom. The conformation is stabilized by two well-conserved hydrogen bond groups, one from the triazine to Arg 702 | Homo sapiens | |
5-(4,6-dimethoxy-1,3,5-triazin-2-yl)-1-(4-methoxyphenyl)pyrrolidin-2-thione | in S-configuration, the compound binds rather low in the site of the enzyme, at the end of the farnesyldiphosphate far from the zinc. In R-configuration, there is a hydrogen bond between one the methoxy groups and Arg 702 | Homo sapiens | |
5-(4,6-dimethoxy-1,3,5-triazin-2-yl)-1-[3-(trifluoromethyl)phenyl]pyrrolidine-2-thione | - |
Homo sapiens | |
ethyl 3-(2,5-dimethoxyphenyl)-1,2-oxazole-5-carboxylate | - |
Homo sapiens | |
Zn2+ | inhibition of human farnesyltransferase by zinc complexation can be improved with triazine-isoxazole moieties. The replacement of the isoxazole unit by a pyrrolidin-2-one is detrimental to the inhibitory activity while the pyrrolidin-2-thione derivatives conserves the biological potential | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | P49354 and P49356 | P49354 i.e. alpha-subunit, P49356 i.e. beta-subunit | - |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.0038 | - |
pH 7.5, 30°C | Homo sapiens | 5-(4,6-dimethoxy-1,3,5-triazin-2-yl)-1-(4-methoxyphenyl)pyrrolidin-2-thione | |
0.0372 | - |
pH 7.5, 30°C | Homo sapiens | ethyl 3-(2,5-dimethoxyphenyl)-1,2-oxazole-5-carboxylate | |
0.0373 | - |
pH 7.5, 30°C | Homo sapiens | 4-[5-(4,6-dimethoxy-1,3,5-triazin-2-yl)-1,2-oxazol-3-yl]-N,N-dimethylaniline | |
0.0411 | - |
pH 7.5, 30°C | Homo sapiens | 5-(4,6-dimethoxy-1,3,5-triazin-2-yl)-1-[3-(trifluoromethyl)phenyl]pyrrolidine-2-thione |